Company news
Neurocrine Biosciences, Inc. news in 2022
Neurocrine Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.
Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
December 21, 2022
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
December 5, 2022
Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022
December 1, 2022
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
November 7, 2022
Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting
November 2, 2022
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
November 2, 2022
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
October 31, 2022
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
October 26, 2022
Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022
October 23, 2022
Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference
October 18, 2022
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
October 10, 2022
Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer
September 28, 2022
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022
September 18, 2022
Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
September 14, 2022
Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress
September 14, 2022
Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners
September 11, 2022
Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 5, 2022
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
August 3, 2022
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
July 13, 2022
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
June 12, 2022
Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 7, 2022
Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
June 5, 2022
Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
June 5, 2022
Neurocrine Biosciences Announces Repurchase of Convertible Notes
May 23, 2022
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
May 22, 2022
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
May 11, 2022
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
May 3, 2022
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
May 2, 2022
Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
May 1, 2022
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
April 12, 2022
Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
March 31, 2022
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
March 27, 2022
Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
March 27, 2022
Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
March 23, 2022
Neurocrine Biosciences to Present at Stifel 2022 CNS Days
March 20, 2022
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
February 10, 2022
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
January 24, 2022
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
January 5, 2022
Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022
Calls in 2022
- Neurocrine Biosciences (NASDAQ:NBIX) Q3 2022 Earnings Call
Nov 1, 2022
Transcript - Neurocrine Biosciences (NASDAQ:NBIX) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Neurocrine Biosciences (NASDAQ:NBIX) Q1 2022 Earnings Call
May 4, 2022
Transcript - Neurocrine Biosciences (NASDAQ:NBIX) Q4 2021 Earnings Call
Feb 11, 2022
Transcript
Decks in 2022
- Q3 2022 Earnings Presentation
Earnings · 40 slides · Nov 1, 2022
- Q2 2022 Earnings Presentation
Earnings · 40 slides · Aug 4, 2022
- Q4 2021 Earnings Presentation
Earnings · 38 slides · Feb 11, 2022
- J.P. Morgan Healthcare Conference 2022
Conference · 22 slides · January 2022